Comparative Pharmacology
Head-to-head clinical analysis: CENTANY versus ZELSUVMI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTANY versus ZELSUVMI.
CENTANY vs ZELSUVMI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Nucleoside analog inhibitor of RNA-dependent RNA polymerase (NS5B polymerase) of hepatitis C virus, incorporating into viral RNA and causing chain termination.
Apply a thin layer to affected area twice daily for 10 days. For perioral dermatitis, apply once daily.
ZELSUVMI (berotralstat) 150 mg orally once daily with food.
None Documented
None Documented
8-10 minutes in serum; prolonged to 15-20 minutes in patients with renal impairment. Clinical context: Rapidly cleared, infrequent dosing intervals (e.g., every 20 minutes during procedure).
Terminal elimination half-life is approximately 19.6 hours in healthy adults, supporting once-daily dosing.
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (85-90% renal); minor biliary/fecal elimination (<5%).
Primarily renal excretion as unchanged drug; approximately 60% recovered in urine and 20% in feces over 72 hours.
Category C
Category C
Topical Antibiotic
Topical Antibiotic